- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: July 2026
Amivantamab – July 2026
- Solution for subcutaneous injection 1600 mg in 10 mL
- Solution for subcutaneous injection 2240 mg in 14 mL
- Solution for subcutaneous injection 2400 mg in 15 mL
- Solution for subcutaneous injection 3520 mg in 22 mL
Public Summary Documents
Last updated
13 November 2026
